Climara Pro Patch
Product Images NDC 50419-491

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Climara Pro (NDC 50419-491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure diagram showing the molecular formulas of Estradiol (E2) and Levonorgestrel (LNG), the active ingredients in Climara Pro 0.045 mg/d and 0.015 mg/d transdermal patches by Bayer HealthCare Pharmaceuticals Inc.*

FDA Label Image

Diagram Patch (Image 02)

An illustration diagram showing the three layers of the Climara Pro transdermal patch. The layers are labeled as (1) Film Backing, (2) Drug-in-Adhesive Layer, and (3) Protective Liner.*

FDA Label Image

Figure 1 (Image 03)

A line graph depicting baseline unconjugated estradiol serum concentration (pg/mL) over time (hours), showing changes from 0 to 168 hours. The graph displays data points connected by a line illustrating the serum levels of estradiol after dosing.*

FDA Label Image

Figure 2 (Image 04)

A line graph showing Levonorgestrel serum concentration (pg/mL) over time (hours). The horizontal axis represents time in hours from 0 to 168, and the vertical axis represents exposure levels from 0 to 250 pg/mL. The graph depicts a fluctuating serum concentration with a peak around 48 to 60 hours and gradual decline thereafter.*

FDA Label Image

Fig 3 (Image 05)

A bar chart comparing percent values over 13 cycles for two treatments, Climara Pro and an Estradiol 44 mg comparator. The x-axis represents cycle numbers (1 to 13), and the y-axis shows percentage values, illustrating a trend of increasing percentages over the cycles for both groups.*

FDA Label Image

Fig 4 (Image 06)

A line graph comparing total lumbar spine bone mineral density percentage change from baseline over treatment cycles between a 4.0 mg estradiol (E2) group and a placebo group. The x-axis shows treatment cycles (Baseline, 6, 13, 19, and 26 cycles), and the y-axis shows percent change from baseline, with error bars depicted for each time point.*

FDA Label Image

Fig A (Image 07)

Climara Pro transdermal patch label displaying the brand name and the active ingredients Estradiol and Levonorgestrel. The patch delivers 0.045 mg/day of estradiol and 0.015 mg/day of levonorgestrel. The label includes dosage form as a once-weekly transdermal system, the labeler Bayer HealthCare Pharmaceuticals Inc., and mentions prescription use only.*

FDA Label Image

C:\users\sgcgy\desktop\jpeg Climara\images Climara Pro\fig B.jpg (Image 08)

An instructional illustration shows how to open a Climara Pro transdermal patch package by tearing along the side and bottom notches. The packaging displays the product name Climara Pro and Bayer logo, highlighting the correct technique for accessing the patch inside the foil pouch.*

FDA Label Image

Fig C (Image 09)

An illustration showing a Climara Pro patch with an arrow indicating the removal of the protective backing from the transdermal patch labeled "Climara Pro." This visual demonstrates how to peel off the protective backing before application.*

FDA Label Image

Fig D.jpg (Image 10)

Illustration showing the Climara Pro transdermal patch with protective backing. The diagram indicates the placement and removal direction of the patch, highlighting the protective backing layer that must be peeled away before application.*

FDA Label Image

Fig E (Image 11)

An instructional illustration showing hands carefully removing a Climara Pro transdermal patch from its packaging. The image includes directional text advising to remove the patch without removing the foil sticker, indicating proper handling of the patch before application.*

FDA Label Image

Fig F.jpg (Image 12)

A black and white line drawing illustrating the application of a transdermal patch on the lower abdomen. The image shows a person's torso from the waist area with one hand placing the rectangular patch onto the skin.*

FDA Label Image

Fig G.jpg (Image 13)

An anatomical illustration depicting the posterior view of the lower torso, showing the buttocks. A hand is applying a small circular transdermal patch to the upper buttock area, demonstrating how to properly place the Climara Pro patch for transdermal delivery.*

FDA Label Image

Fig H (Image 14)

An illustration showing a hand applying a small round patch to skin, demonstrating the method for using a transdermal patch, likely indicating how to place Climara Pro patch on the body.*

FDA Label Image

Climara Pro Carton (Image 15)

Climara Pro 0.045/0.015 mg/day patch packaging label for Estradiol and Levonorgestrel transdermal system by Bayer HealthCare Pharmaceuticals Inc. The label shows a 4-system box with dosage and application instructions noted, highlighting once-a-week use and the 0.045 mg estradiol and 0.015 mg levonorgestrel strengths per day.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.